Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development

NEW HAVEN, Conn., Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
August 08, 2018 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

Clinical programs in neuroscience (BXCL501) and immuno-oncology (BXCL701) on track Company strengthens business operations and infrastructure NEW HAVEN, Conn., Aug. 08, 2018 (GLOBE NEWSWIRE) --...
August 07, 2018 07:02 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience

NEW HAVEN, Conn., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
August 02, 2018 16:05 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update

Conference call scheduled on August 8, 2018 at 4:30 PM ET NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical...
August 02, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference

NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
July 31, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma, Ph.D. as Vice President of Business Development

NEW HAVEN, Conn., July 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
July 24, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal

Nature Medicine article expands upon mechanistic findings and presents DPP8/9 inhibition as potential treatment for various cancer types BXCL701 being developed for two rare malignancies: pancreatic...
July 10, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501

NEW HAVEN, Conn., July 10, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
June 27, 2018 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development

Optimal exposure levels for developing BXCL501 sublingual thin film identified Results support clinical evaluation of dexmedetomidine in acute treatment of agitation resulting from neuropsychiatric...
June 26, 2018 08:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Added to Russell Microcap® Index

BRANFORD, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...